Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiangshao granules plus SSRIs for depression in women
ChiCTR2300071665Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jan 2023
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Xiangshao Granules, escitalopram, citalopram, fluoxetine, paroxetine and 2 more in major depressive disorder (MDD), sponsored by The Second Xiangya Hospital. Primary endpoint: Hamilton Depression Rating Scale-24. Started Jan 2023; status: recruiting.
02
Drugs
Xiangshao Granulesescitalopramcitalopramfluoxetineparoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2300071665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071665.